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Gastric neuroendocrine tumors (g-NETs), which originate from gastric enterochromafﬁn-like (ECL)
mucosal cells and account for 2.4% of all carcinoids, are increasingly recognized due to expanding in-
dications of upper gastrointestinal endoscopy.
Often silent and benign, g-NETs may however, be aggressive and sometimes they mimic the course of
gastric adenocarcinoma.
Current nosography distinguishes those occurring in chronic conditions with hypergastrinemia, as the
type 1 associated with chronic atrophic gastritis, and the type 2 associated with ZollingereEllison
syndrome in MEN1.
Conversely, type 3 and 4 (according to some authors) are unrelated to hypergastrinemia and are
frequently malignant, with a propension to develop distant metastases.
While there is a general agreement concerning the treatment of malignant gastric neuroendocrine
tumors, for types 1 and 2, current possibilities include surveillance, endoscopic polypectomy, surgical
excision, associated or not with surgical antrectomy, or total gastrectomy.
This report, based on our clinical experience, discusses how the size, number, depth, histological
grading, staging with CT, MRI, and the use of recently developed somatostatin receptor tracers (68Ga-
DOTATATE, 68Ga-DOTA-TOC) could allow the correct identiﬁcation of a benign or malignant propensity
of an individual tumor, thus avoiding underestimation or overtreatment of these uncommon neoplasms.
© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
The neuroendocrine tumors of the stomach represent a wide
spectrum of neoplasms that arise mainly from gastric
enterochromafﬁn-like (ECL) cells.
According to data from the Surveillance, Epidemiology and End
Results program (SEER) in the US, well differentiatedavallaro), amzanghi@unict.it
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by Elsevier Ltd. All rights reservedneuroendocrine tumors (NETs) of the stomach demonstrated a
tenfold incidence increase in the US in the last 30e35 years. The
prevalence in the US of gastrointestinal well differentiated NETs has
recently been calculated at 35/100,000 [1e3].
A recent analysis [4,5] of the National Cancer Institute SEER
database by Modlin et al. demonstrated that, from 1992 to 1999,
gastric NETs comprised 8.7% of all gastrointestinal carcinoid tumors.
Nowadays most neuroendocrine tumors of the stomach are
diagnosed at an early stage because of the widespread use of upper
gastrointestinal endoscopy. Moreover the diagnostic strategies, the
management, and the prognosis has improved greatly over time.
According to a recent analysis of the SEER data by Landry et al.
[6] 5-year-survival is now as high as 71%. We describe two cases of.
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affected by multifocal type I gastric NET with locoregional lymph-
node metastases and one case of type III gastric NET with syn-
chronous adenocarcinoma of the stomach. In both cases an
accurate diagnostic workup with 68Ga-DOTA-TOC CT-PET has
signiﬁcantly inﬂuenced the surgical strategy.
1.1. Our experience
Seven patients (pts) were treated in our institution between
January 2006 and December 2012 for gastric neuroendocrine
neoplasm. All lesions, incidentally discovered, were <10 mm. All
patients except three, were successfully treated endoscopically. No
recurrence has been recorded in our series. Interestingly two pa-
tients demonstrated unexpected node involvement in perigastric
lymphnodes. Their clinical history and management will be
described.
1.2. Case n. 1
A 60 year old white woman, with a 12-mo history of dyspeptic
symptoms and mild weight loss, presented to our surgical
department.
Her medical history was signiﬁcant for an autoimmune atrophic
gastritis, macrocytic anemia (Hb: 7.8 g/dl, MCV: 115 fL, vit.B12:
<150 pg/ml, Ab-anti parietal cells positive) and a sensory neurop-
athy. Physical examination was negative except for a slight distal
dysesthesia (glove shaped/sock shaped) and moderate ataxia
attributable to the aforementioned peripheral neuropathy.
The upper endoscopy showed a polypoid neoformation (7 mm)
within an irregularity of the sub-cardial gastric mucosa. It
demonstrated also a mucosal deformity, with surrounding ero-
sions, located in the antrum: several biopsies were performed.
The histological examination revealed a multifocal, well-
differentiated endocrine tumor, with muscularis mucosae inva-
sion, on a contest of severe chronic atrophic gastritis, widespread
intestinal metaplasia and foci of low-grade dysplasia.
The proliferative activity (Ki-67, MIB1 index) was below 2%. The
immunohistochemistry stained positive for synaptophysin and
chromogranin A.
The determination of serum gastrin (normal value <50 pg/ml)
and chromogranin A (vn 19.4e98 pg/ml) demonstrated respec-
tively values of 698 pg/ml and 298 pg/ml.
The biochemical markers of renal function, liver, pituitary and
parathyroid were within normal range.
To assess the degree of inﬁltration an ultrasonographical
endoscopy was performed: it revealed a hypoechoic thickening of
muscular and submucosal layer located in the incisura angularis
(7 5mm), and a hypoechoic thickening of mucosa and submucosa
of the gastric body (8 mm).
Some lymph nodes of uncertain nature (6e7 mm) were
observed along the lesser curvature and a group of nodes was
detected medially to the arc of the splenic artery.
The CT scan conﬁrmed the presence of nodes enlargement
(7 mm) along the left gastric artery (station 7 according JGCA) and
the presence of some nodes surrounding the proximal splenic ar-
tery (station 11p according JGCA). There was no evidence of distant
mestastases.
Despite the US and CT scan evidence, the nature of those nodes
was still not clear thus body receptor scintigraphy was also
performed.
The 111-In Octreoscan was performed using thoracic WB/SPECT
methodic and abdominal SPECT detection at 4, 24, 48 h after in-
jection of the tracer: no pathological accumulation of tracer was
detected.The Total body CT-PET with 68-Ga-DOTA-OctreoTATE (DOTA-
TATE) was also performed: tracer accumulation was detected on
the gastric wall and also detected on 7-9-11p gastric lymphnode
stations. No distant metastases were found (Fig. 1).
The patient underwent total gastrectomy with meticulous D2
lymphadenectomy paying particular attention on harvesting all
nodes surrounding the proximal splenic artery.
The post operative course was regular and complication free,
patient was discharged in post operative day 8.
Histological examination of the surgical specimen conﬁrmed
the diagnosis of multifocal neuroendocrine tumors inﬁltrating the
muscularis, with metastasis to regional lymph nodes (T2 Nþ).
1.3. Case n.2
A 66 year old white male presented to our surgical unit with a
past medical history signiﬁcant for hypertension. Physical exami-
nation was negative except for a slight epigastric pain.
The Upper endoscopy showed some irregularities of mucosa
along the posterior wall of the stomach: several biopsies were
performed. The histological examination revealed a well-
differentiated endocrine tumor (synaptophysinþ, chromogranin
Aþ, Ki 67 proliferative activity < 2%).
The determination of serum chromogranin A (vn 19.4e98 pg/
ml) demonstrated a value of 135 pg/ml. The values of gastrin, renal
function, liver, pituitary and parathyroid were within normal
range.
To assess the degree of inﬁltration an ultrasonographical
endoscopy was performed: it revealed a hypoechoic thickening of
muscolar and submucosal layer located in the posterior wall of the
stomach, and a hypoechoic thickening of mucosa and submucosa of
the gastric body (8 mm). It also revealed no perigastric lymphnode
enlargement. There was no evidence of enlarged nodes in the
mesentery root or along the 7e9 node stations.
The CT scan conﬁrmed the presence of a multiple gastric wall
thickening (2 cm) and the presence of nodes enlargement in the
splenic hilum of uncertain nature (station 10 according JGCA).
There was no evidence of distant mestastases.
Because of the synchronous nature of endocrine tumors, the
111-In Octreoscan was performed: no extragastric clear patholog-
ical accumulation of tracer was detected.
Total body CT-PET with 68-Ga-DOTA-OctreoTATE (DOTATATE)
was also performed: the tracer accumulation, detected on the
gastric wall, was multifocal. Tracer accumulation was also detected
in the splenic hilum. No distant metastases were found (Fig. 2).
The patient underwent total gastrectomy with D2 lymphade-
nectomy, extendend to the splenic hilum.
Post operative course was regular, the patient was discharged in
P.O.D. 7.
The histological examination of the surgical specimen
conﬁrmed the diagnosis of synchronous multifocal neuroendocrine
tumor inﬁltrating the muscular wall, with metastasis to regional
lymph nodes in the splenic hilum (T2 Nþ).
2. Discussion
2.1. Classiﬁcation
An optimal management of gastric NETs implies an accurate
study of the type, biology, and stage of the tumor as well as the
individual situation.
The World Health Organization (WHO) classiﬁcation distin-
guishes well differentiated NETs, well differentiated neuroendo-
crine carcinomas, and poorly differentiated neuroendocrine
carcinomas of the stomach.
Fig. 1. 68-Ga-DOTATOC: lymph nodes of uncertain nature (6e7 mm) along the lesser curvature and a group of nodes medially to the arc of the splenic artery.
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iting histological angioinvasion or invasion of the muscularis
propria or that have metastasized.
Stage is determined, according to the TNM classiﬁcation, by
tumor size, depth of invasion, and the presence of lymph node and
liver metastases [6e8].
According to the proliferative activity, gastric NETs are graded as
G1 (Ki-67: 0e2%), G2, (Ki-67:3e20%) or G3 (Ki-67: >20) [6e9].
The commonly used clinicopathological classiﬁcation of the
gastric NETs distinguishes fourth types of neuroendocrine neo-
plasms of the stomach [9e11].2.1.1. Type 1
About 70%e80% of gastric neuroendocrine neoplasms are
associated with fundic chronic atrophic gastritis (often autoim-
mune) and enterochromafﬁn-like (ECL) cell hyperplasia.
Patients have a mean age of 50 years and female sex is the more
involved [11e14].
These tumors generally present (in 75% of cases) as multifocal
polypoid mucosal protrusions (<10 mm) in the corpus and/or
fundus of the stomach. Enterochromafﬁn, Enterchromafﬁn-like or
somastatin cells can be identiﬁed: these tumors commonly express
synaptophysin, chromogranin A, monoamine transporter 2 and
often alfa-HCG [10].
The proliferative activity (Ki-67, MIB1 index) usually is 2% or
below.
Type 1 NETs are minimally invasive with 90% conﬁned to the
mucosa or submuscosa and only 10% invading the muscularispropria. Only 2e9% of patients presents lymph node metastase. In
particular lymph node metastases are generally associated with
tumors greater than 20 mm, inﬁltrating the muscularis propria or
angioinvasive [8e13].
The 5-and 10-year survival of those patients appears not to
differ from those of the general population [11,13,15].2.1.2. Type 2
About 5% of all gastric NETs occur in patients affected by mul-
tiple endocrine neoplasia type 1 (MEN1) and ZollingereEllison
syndrome (ZES), primarily caused by a duodenal or pancreatic
gastrinoma.
Gastric NETs develop in 15e30% of ZES/MEN1 patient:
conversely, rare is the ﬁnding of GNETs in sporadic ZES.
Both sex are equally involved with a mean age, at the time of the
diagnosis, of 45 years.
Similarly to type 1 tumors, type 2 gastric NETs are thought to
originate from ECL cells. However, unlike type 1 tumors, both chief
and parietal hyperplastic cells are contained in the mucosa. Type 2
gastric NETs typically express synaptophysin, chromogranin A,
monoamine transporter 2 [10].
These tumors are generally small (<15 mm), almost multiple
(92%) and limited to the submucosa/mucosa (90%) [13,14,16]. Risk
factor for nodal involvement or metastases are tumor dimension
(>20 mm), muscularis propria inﬁltration and angioinvasion
[13,17].
The proliferative activity (Ki-67, MIB1 index) usually is 2% or
below.
Fig. 2. 68-Ga-DOTATOC: tracer accumulation of uncertain nature, detected in the
splenic hilum.
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The 5-year survival rate is about 60%e75%: however this unfa-
vorable rate is mainly related to the ZES/MEN1: tumor related
deaths in this group has been described in fever than 10% [15,16].
2.1.3. Type 3
About 15e25% of all gastric NETs are sporadic neoplasm not
associated with hypergastrinemia or ECL hyperplasia. The mean
age of incidence is 50 years. Their proliferation rate often exceeds
the 2% cut off level commonly shown by type 1 and 2 gastric NETs.
At the time of diagnosis they often inﬁltrate the muscularis propria
and become angioinvasive: most patients have already developed
metastasis (liver or locoregional nodes) [11,14].
Tumor related death from type 3 gastric NETs is seen in 25%e
30% of patients, and the 5-year survival is 50% or less [11,14,15].
2.1.4. Type 4
According to some authors this group describes poorly differ-
entiated solitary neuroendocrine carcinomas. They were lacking in
the original classiﬁcation by Rindi et al [9,14].At the time of the diagnosis these tumors are often ulcerated
and their dimension is considerable (50 mm or greater). Inﬁltration
and angioinvasivity is common: their proliferation rate usually
exceed 20%.
Their immunohistochemical stain express synaptophisin but
rarely chromogranin or VMAT2 [10].
Histologically these tumors demonstrate a pattern reminiscent
of small or large cell neuroendocrine lung carcinoma. Sometimes
adenocarcinoma of squamous carcinoma elements are mixed.
Half of the patients affected by this disease diewithin 12months
[8,9,18].2.2. Diagnostic workup
Type I and II gastric NETs are almost an incidental ﬁnding during
a routine upper gastrointestinal endoscopy.
Type II gastric NETs in patients affected by ZES/MEN1 could be
diagnosed because of gastroesophageal reﬂux disease, recurrent
peptic ulcer, chronic diarrhea, gastrointestinal bleeding, anemia
and dyspepsia.
Type III and IV may also be symptomatic: bleeding, chronic
diarrhea and loss of weight are the symptoms often described.
Occasionally an atypical carcinoid syndrome with prolonged
ﬂushing that affect the extremities or the trunk could be the
exordium.
The diagnostic workup implies an upper endoscopy with several
tumor biopsies.
It is recommended to perform a sampling not only of the sus-
pected lesions but also of the fundus (four samples) and a sampling
of the antrum (two samples) to evaluate the presence of atrophic
gastritis and the degree of ECL hyperplasia [16e19].
Biopsies must be stained for chromogranine and synaptophysin.
An accurate calculation of mitotic count and Ki/67 index is
mandatory [11,16e19].
Endoscopic ultrasound is the main technique to evaluate the
tumor size and depth of invasion: moreover EUS can also allow
ﬁne-needle aspiration of submucosal lesions.
Abdominal and Thoracic CT scan is useful to stage the disease, to
ﬁnd distant metastases and to evaluate the degree of node
involvement.
Somatostatin receptor scintigraphy is useful to complete the
staging of the disease.
A determination of serum gastrin and chromogranin A is always
recommended. Secretin stimulation test should be performed
when suspecting the presence of a ZES and proton pump inhibitors
should be suspended for 7e8 days. Evaluation of intrinsic factor
antibodies, Vit B12 serum levels and an accurate histological
mapping of gastric fundus could help in the differential diagnosis
between a solitary type 1 or type 3 gastric NET.
The 5-hydroxylindoleacetic (5-HIAA) acid concentration in a
24 h urine collection, histamine metabolites or 5-
hydroxytryphophan test may be useful in patients that exhibit
carcinoid typic or atypic syndrome [11,17e20].2.3. The role of somatostatin receptor tracers
Neuroendocrine tumors are able to over-express somatostatin
receptors (SSTRs) in a pattern related to tumor type, origin, and
grade of differentiation.
To date 5 receptor subtypes have been characterized
(SSTR1eSSTR5): SST2, SST3 and SST5 receptors bind to the so-
matostatin analogue octreotide and are expressed in 85%e100% of
gastrointestinal and pancreatic NETs. In most cases, SST2 receptor is
overexpressed [21,22].
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The most widely used tracer for scintigraphy is 111In-DTPA-
octreotide (111In-DTPAOC, Octreoscan).
The sensitivity of 111In-DTPAOC for the detection of NETs has
been variously reported between 67% and 100%. However, quite
recently, SST positron emission tomography (PET) has shown its
diagnostic superiority over scintigraphy in several studies
[23e26].
In comparison to scintigraphy, positron emission tomography
has a two to threefold higher spatial resolution (3e6 mm versus
10e15 mm) and facilitates quantiﬁcation of tracer uptake.
Although 18F-FDG PET shows high spatial resolution, unlike for
many other malignancies, it is not indicated primarily for NET
because of its poor sensitivity to detect tumors with low metabolic
activity and slow growth.
The compound most often used in functional imaging with PET
is 68Ga-DOTATOC.
The afﬁnity of 68Ga-DOTATOC in binding SSTR2 is 2.5 ± 0.5 nM:
it has been proven tenfold higher than that of 111In-DTPAOC
(22 ± 3.6 nM) [22].
Two studies evaluating four and eight patients, respectively,
demonstrated 68Ga-DOTATOC PET to be more efﬁcient than 111In-
DTPAOC single-photon emission computed tomography (SPECT) in
the detection of small NET lesions [23,24].
In 2007 Buchmann et al. prospectively examined twenty-seven
NET patients: the authors concluded that 68Ga-DOTATOC PET is
superior to 111In-DTPAOC SPECT in the detection of NET manifes-
tations in the lung and skeleton and similar for the detection of NET
manifestations in the liver and brain. They focused the advantage of
68Ga-DOTATOC in guiding the clinical management [25].
Gabriel M et al. (2007) prospectively studied eighty-four pa-
tients. According to their study Somatostatin receptor PET with
68Ga-DOTA-TOC is superior compared with SPECT and CT in
various clinical situations (initial diagnosis, staging, and follow-up).
The higher sensitivity for tumor detection has clinical impact in a
considerable number of patients, especially when compared with
CT. The more accurate results are achieved by the combination of
PET and CT [26].
Recently the use of 68Ga-DOTATATE over 68Ga-DOTA-TOC has
been proposed: however according Poeppel TD et al. (2013) the
approximately 10-fold higher in vitro afﬁnity for the sst2 of 68Ga-
DOTATATE has not proven to be clinically relevant [27].
Peptide receptor radionuclide therapy (PRRT) with radiolabelled
somatostatin analogues plays a growing role in the treatment of
patients with inoperable or metastatic gastroenteropancreatic
neuroendocrine tumors [28].
90Y-DOTATOC and 177Lu-DOTATATE (Yttrium-90 and Lutetium-
177 beta emitters) nowadays are the most used radiopeptides for
PRRT. The results that are very encouraging in terms of tumor
regression (tumor response rates: 15e35%) and in terms of patients
self-assessed quality of life.
Side effects are few and mild but amino acids should be used for
kidney protection, especially during infusion of 90Y-DOTATOC.
Individual dosimetry could prevent damage to bone marrow
and normal organs especially when different mixture of radio-
peptides are administered.
Options to improve PRRT may include combinations of radio-
active labelled somatostatin analogues and the use of radio-
sensitising drugs combined with PRRT.
The neo-adjuvant treatment and adjuvant therapy cycles in
patients with progressive disease, after surgery have been pro-
posed but further evidences are required.
If more widespread use of PRRT can be accomplished, PRRT may
well become the therapy of ﬁrst choice in patients with metastatic
or inoperable GEP-NETs [28e30].2.4. Management
Treatment strategies are greatly inﬂuenced by the type, grade
and stage of the gastric NET.
Muscular wall inﬁltration, increased proliferation (Ki67 > 2%),
and angioinvasion are considered risk factor for metastatic disease.
The invasion of the muscularis propria, angioinvasion, increased
proliferation activity and the presence of nodal involvement lead an
indication to surgical treatment even in well differentiated tumors.
Type 1 or 2 gastric NET that are 10 mm or smaller, in absence of
risk factor like the aforementioned muscular wall inﬁltration,
increased proliferation or angioinvasion, can either be managed
conservatively with endoscopic surveillance (<10 mm) or removed
by endoscopic mucosal resection (<20 mm): the specimen will be
examined for histological signs of angioinvasion and evaluation of
the proliferation activity. Surveillance by gastroscopy is repeated at
12e14 months intervals after the endoscopic treatment [11,15].
Despite the controversies in management of type 1 or 2 gastric
NETs, there are no reports in the literature inheriting clinical rele-
vant local recurrencies after polypectomy or mucosectomy of small
(<20 mm) type I or II gastric NETs: the available retrospective data
do not argue for a survival beneﬁt of the surgical versus non sur-
gical treatment of these small tumors when they are lacking risk
factors. Conversely, small type 1 or type 2 (<20mm) GNETsmust be
considered for surgery if they become angioinvasive, inﬁltrate the
muscular wall, show G2 grading or have metastasized. Treatment
recommendations for type 2 gastric NETs can only be based on case
reports and small case series: they are often multiple and hyper-
gastrinemia cannot be easily solved surgically, thus, according to
some authors, total gastrectomy is often preferred to partial gas-
trectomy. However, especially in elderly patients, conservative or
minimally invasive surgical therapy may be preferred. Treatment
with somatostatin analogues could help in reducing the number
and recurrence of small type 2 tumors in patient not candidated to
surgery [31,32].
The treatment of type 2 GCs is further complicated by the
controversies regarding the treatment of gastrinoma in MEN-1.
Currently, no deﬁnitive evidence exists that surgery increase the
survival or disease free survival in MEN-1. The role of duodenal-
pancreatic surgery in patients with MEN-1 who have pharmaco-
logically controllable ZES and no other clinically evident hormonal
related syndrome is still object of debate.
Surgery is also the treatment of choice for type 3 gastric NETs
(>10 mm) and localized type 4 poorly differentiated tumors. Only
small (<10 mm) type 3 G1 gastric NETs conﬁned to mucosa may be
treated by endoscopic mucosectomy [11,15].
Because of the favourable tumor biology, surgery and or local
ablation should be considered even in metastatic disease. Liver
metastases should be treated by hepatic resection, ablative thera-
pies, arterial embolization, radioembolization or peptide receptor
targeted therapy. In the case of systemic, non resectable disease
cytostatic therapy is generally advised. Exocrine-endocrine tumors
(commonly called “collision tumors”) share the diagnostic workup
and the therapeutic strategies with the usual type of gastric
carcinoma.
Long-acting somatostatin analogues are the drugs of choice for
the medical control of the carcinoid syndrome (generally atypical)
with promising results in 70%e90% of patients.
I they fail alpha interferon could be used. Moreover PPIs (pro-
tonic pump inhibitors) are the medical treatment of choice for ZES
if surgical treatment fails [16,17,21,22].
2.4.1. Follow up and endoscopic surveillance
Surveillance by endoscopy with biopsies is recommended every
3e5 years in patient with fundic autoimmune or atrophic gastritis.
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2e3 years. If type 1 gastric NET disease has been diagnosed
endoscopic histological surveillance is recommended every 12
months for recurring patients, and any 24months for not-recurring
cases. In case of type 2 tumors, endoscopy should be repeated
yearly. In patients with type 3 tumors, followup should depend on
tumor subtype and is conﬁdent with program suggested for gastric
adenocarcinoma. Biopsies of every mucosal lesion should be per-
formed. Follow-up should include radiological investigations (CT
scan/MRI) and CgA [33e35].
3. Conclusions
Gastric lesions are often found during endoscopic examination
of upper gastrointestinal tract. Those range from benign (i.e., fundic
gland polyp, hyperplastic polyp, hamartomatous polyp, pancreas
rest) to premalignant or malignant lesions (i.e., adenoma, neuro-
endoscrine tumors [G-NET] gastrointestinal stromal tumor [GIST],
MALT lymphoma, adenocarcinoma) [36e40].
An accurate preliminary differential diagnosis is necessary,
especially when ZES/MEN1 is suspected [41].
Our experience clearly demonstrates how an accurate diag-
nostic workup and the integrationwith 68Ga-DOTATOC CT-PET has
a great inﬂuence in the correct management of gastric neuroen-
docrine tumors.
In the ﬁrst case we describe a multifocal type 1 endocrine tu-
mor: the adoption of ad US gastric endoscopy showed the suspicion
of involvement of regional lymph nodes. This placed the indication
for further diagnostic investigations.
In the second case we describe a multifocal type 3 endocrine
tumor: it demonstrated nodes involvement at the splenic hilum.
We would like to emphasize about the importance played by CT
e PET with Ga- 68 e DOTATOC to obtain a correct staging and then
a proper treatment of the patients [23e26].
In our experience the surgical strategy was elaborated owing to
the PET ﬁndings. The lymphadenectomy and the entity of gastric
resection were extended with the aim of R0 resection.
Further parameters need to be evaluated to identify the small
subset of patients that will develop more aggressive disease [42].
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